Search results
Results from the WOW.Com Content Network
GINA conducts continuous review of scientific publications on asthma and is a leader in disseminating information about the care of patients with asthma. [2] GINA publishes resources such as evidence-based guidelines for asthma management, and runs special events such as World Asthma Day. GINA's guidelines, revised each year, are used by ...
Systematic review and individual patient data meta analysis research [15] in the centre has shown that, even with little training, people on oral anticoagulation can successfully self-monitor, and even self-manage their disease in the community. [16] Patients capable of self-monitoring and self-adjusting therapy have fewer thromboembolic events ...
An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...
The Centers for Disease Control and Prevention estimate that 1 in 11 children and 1 in 12 adults have asthma in the United States of America. [1] According to the World Health Organization, asthma affects 235 million people worldwide. [2] There are two major categories of asthma: allergic and non-allergic.
The strongest risk factor for developing asthma is a history of atopic disease; [66] with asthma occurring at a much greater rate in those who have either eczema or hay fever. [80] Asthma has been associated with eosinophilic granulomatosis with polyangiitis (formerly known as Churg–Strauss syndrome), an autoimmune disease and vasculitis. [81]
In 2000-2001 asthma prevalence was monitored at 6.5%; by 2010-2011 a 4.3% increase was shown, with asthma prevalence totaling 10.8% of Canada's population. [29] Furthermore, asthma prevalence varies among the provinces of Canada; the highest prevalence is Ontario at 12.1%, and the lowest is Nunavut at 3.8%. [29]
There is a strong association of C. pneumoniae with long-standing asthma among the non-atopic asthma in comparison to atopic asthma. [2] In fact, the severity of asthma can be determined by the elevated titres to C. pneumoniae, but not to other potential pathogens such as Mycoplasma pneumoniae, adenovirus, influenza A and B or parainfluenza ...
AERD affects an estimated 0.3–0.9% of the general population in the US, including around 7% of all asthmatics, about 14% of adults with severe asthma, and ~5-10% of patients with adult onset asthma. [2] [3] [8] AERD is uncommon among children, with around 6% of patients, predominantly female, reporting disease onset during childhood. [9]